IREN is not appealing because management takes huge compensation packages while the company loses money and revenue declines sequentially. That is poison for a company whose cost of capital is literally its own share price. It would look more appealing if it used the tighter credit CoreWeave and Nebius recently tapped instead of funding capex through equity dilution. x.com